Breast

E1: Outcomes in breast and axillary surgery and perioperative complications after neoadjuvant durvalumab plus chemotherapy in triple-negative breast cancer

E10: Patterns of Ipsilateral Breast Tumor Recurrence by Race and Ethnicity: A Population-Based Analysis

E11: Effect of tamoxifen on proliferation of background normal lobules in breast disease.

E12: Are Clinically Node-Negative Patients with a Positive Preoperative Axillary Lymph Node Biopsy Appropriate Candidates for Sentinel Lymph Node Biopsy?

E13: Locoregional Therapy Patterns in Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer

E14: Germline Genetic Testing for Patients with Breast Atypia

E15: National Variation in Implementation of Sentinel Lymph Node Biopsy for Clinically-Node Positive Patients Undergoing Neoadjuvant Therapy

E16: Differences in Rates of Pathological Complete Response and Overall Survival in Patients with Triple Negative Breast Cancer Based on HER2 Status and Race/Ethnicity

E17: Omission of Axillary Lymph Node Dissection in Patients with Residual Nodal Disease After Neoadjuvant Chemotherapy

E18: Clinical Trial Eligibility and Enrollment among Breast Cancer Patients at an Academic NCI designated Cancer Center: Implications for understanding trial disparities

E19: Delays in breast cancer surgery during the COVID-19 pandemic: A population-based analysis

E2: Differential Prognostic Value of Residual Nodal Burden in Breast Cancer Subtypes

E20: Ki67 Gene Expression Was Associated with Complete Response to Neoadjuvant Chemotherapy but with Worse Survival in ER+/HER2- Breast Cancer

E21: Axillary Lymph Node Dissection Should Not Be Avoided in Patients Who Undergo Neoadjuvant Chemotherapy for a Positive Sentinel Node after Targeted Axillary Staging

E22: Agonistic CD40 increases infiltration and spatial organization of cytotoxic CD8 T cells in hormone receptor positive murine breast cancer

E23: Immunohistochemical Status Predicts Pathologic Complete Response to Neoadjuvant Therapy in HER2 Overexpressing Breast Cancers

E24: Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer after Neoadjuvant Chemotherapy

E25: Is adjuvant chemotherapy being overused or underused in women aged < 50 with HR+ HER2- breast cancer in the National Cancer Database?

E26: Males with Hormone-Receptor Positive Breast Cancer Treated with Endocrine Therapy Have Worse Survival Than Females

E27: Using the combined 70- and 80-gene signatures on core needle biopsy to guide neoadjuvant chemotherapy recommendations for invasive breast cancer in a Black population: Can we identify those who benefit most at time of diagnosis?

E28: Patient Reported Outcomes from a multi-site, prospective Pivotal study evaluating pegulicianine fluorescence guided surgery (pFGS) for breast cancer lumpectomy procedures using the Lumicell Direct Visualization System (DVS)

E29: Impact of Incision Design During Skin- and Nipple-Sparing Mastectomy with Breast Reconstruction on Postoperative Outcomes

E3: MRI to predict upstaging of DCIS to invasive cancer at the time of surgery

E30: Trends in the Application and Match Rates of the SSO Breast Surgical Oncology Fellowship Program

E31: Oncologic safety of immediate lymphatic reconstruction in breast cancer patients who require axillary lymph node dissection: no increase in distant recurrence

E33: Breast Cancer Survivors as Enablers of Change: Results from a Pilot Feasibility Study of a Stigma Reduction Intervention in Tanzania

E34: Impact of Intraoperative Consultation with Frozen Section versus Cavity Shave Margins on Need for Re-excision and Operative Times

E35: Positive Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy: Can Completion Axillary Lymph Node Dissection Be Safely Omitted?

E36: Commission on Cancer Center Performance with Timeliness of Breast Cancer Treatment Quality Measures

E37: Value Implications of Facility Type in Breast Conservation Surgery: A Comparative Analysis of Tertiary and Community-Based Hospitals

E38: Breast Cancer Presentation and Treatment Patterns in Sexual and Gender Minorities: An Institutional Experience

E39: Regional Variation in De-Escalated Locoregional Therapy in Older Adults with Early-Stage, Hormone Receptor-Positive Breast Cancer

E4: Circulating tumor cell mechanical conditioning (MeCo) score- a predictor of metastatic risk in early-stage breast cancer

E40: Implementation of Perioperative Analgesia Pathways Reduced Opioid Prescribing After Breast Surgery

E41: Persistent Opioid Use in Women Undergoing Curative-Intent Breast Cancer Surgery in 2020

E42: Implant Outcomes Following Breast Conservation Therapy in Patients with History of Augmentation Mammoplasty

E43: Biology is Queen: 21 gene recurrence score has stronger prognostic ability than lymph node burden

E44: Surgical Management of the Axilla in Patients Presenting with Clinically Node Positive Hormone Receptor Positive, HER2 Negative (HR+/HER2-) Breast Cancer

E45: Access to results of patient reported outcome surveys did not improve longitudinal patient reported outcomes in breast cancer patients

E46: Predictors of Pathologic Complete Response with Neoadjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer

E47: Adoption of Modern Radiation Therapy Guidelines and Techniques in Older Women with Early-Stage Breast Cancer

E48: Impact of Race on Cytokine Profiles in Patients with Triple-Negative Inflammatory Breast Cancer: An Exploratory Analysis

E49: Survival Outcomes in Patients with de novo Stage IV Breast Cancer after Primary Tumor Resection

E50: National Trends, Complications, and In-hospital Outcomes for Patients Undergoing Immediate Implant-based versus autologous-based Breast Reconstruction: A Propensity Score Matched Analysis

E51: The association between cirrhosis and outcomes amongst female patients undergoing surgery for breast cancer in Ontario: a population-based study

E52: A prospective observational international real-world evidence-based collaborative platform for Investigator-Initiated studies in early-stage breast Cancer with MammaPrint and BluePrint: The FLEX Study

E53: Local Recurrence Among Patients Treated with Nipple Sparing Mastectomy After Neoadjuvant Chemotherapy

E54: Differences in Time to Surgery Predict Rural-Urban Differences in Survival among Women with Invasive, Non-Metastatic Breast Cancer

E55: Optimizing Treatment Decisions in Microinvasive Ductal Carcinoma in Situ: Evaluating the Need for Surgical Axillary Staging

E56: Can sentinel lymph node biopsy be safely avoided in women undergoing mastectomy for DCIS?

E57: Poverty's Shadow on Survival: Examining the Impact of Persistent Neighborhood Poverty on Breast Cancer Outcomes

E58: Staging for de novo Metastatic Breast Cancer: Can genomic data make it better?

E59: Is it Surgery or Biology? Comparing Overall Survival and Disease-free Survival between Breast-conserving Therapy and Mastectomy by Breast Cancer Phenotype

E6: Comparison of Targeted Axillary Dissection versus Sentinel Node Biopsy Alone on Nodal Recurrence for Patients with Node-Positive Breast Cancer treated with Neoadjuvant Chemotherapy

E60: Incidence of high-risk lesions in women with germline pathogenic variants in BRCA1/2, PALB2 and other breast cancer susceptibility genes undergoing risk-reducing mastectomy

E61: Neighborhood Disadvantage Predicts Higher Serum Cortisol Levels in Breast Cancer Patients

E62: Upstaging from cT1 to pT2 in Triple Negative and Her2 Positive Breast Cancer: an Opportunity to Identify cT1 Breast Cancer Patients for whom Neoadjuvant Chemotherapy Should be Considered

E63: Is Omission of Sentinel Node Biopsy (SLNB) for Low Risk Invasive Breast Cancers safe?

E64: Comparison of characteristics between asymptomatic/screen-detected breast cancer versus symptomatic breast cancer

E65: Positive pegulicianine fluorescence in the lumpectomy cavity correlates with tumor distance to margins

E66: Trends in Contralateral Prophylactic Mastectomy in the Setting of New Society Guidelines

E67: Disparities, Time to Surgery, and Survival in Contralateral Prophylactic Mastectomy: A Review of the National Cancer Database

E69: Outcomes for Modified Oncoplastic Lift and Lymphatic Excision and Reconstruction with Radiation

E7: Multi-Institution Review of Contralateral Axillary Metastases: Time for Reclassification as a Local-Regional Event?

E70: Precision Oncology for Sarcomas of the Breast – Histology-Based Approach at a High-Volume Referral Sarcoma Center

E71: Cause-Specific Survival for Inflammatory Breast Cancer in Hawaii vs. US

E72: Assessment of Axillary De-escalation Following Neoadjuvant Chemotherapy in Occult Primary Breast Cancer

E73: Radial Scar Upgrade Rate After Excisional Biopsy

E74: National Patterns of Axillary Management for Positive Sentinel Lymph Nodes after Neoadjuvant Chemotherapy for Breast Cancer

E75: Breast Cancer in the Immediate Aftermath of COVID-19: Bigger Tumors, More Positive Nodes, Same Surgery.

E76: Epidemiology, treatment and outcomes of males diagnosed with breast cancer in Ontario, 2007-2017: a population-based analysis

E77: Nipple Preserving Surgical Candidates in Male Breast Cancer Patients

E78: Use of Genomic Testing for Locally Recurrent Estrogen Receptor-Positive Breast Cancer

E79: Neoadjuvant Chemotherapy in T1cN0 Triple Negative Breast Cancer

E8: Breast Cancer Care Disparities in Sexual Minority Women: An Analysis of the National Institutes of Health All of Us Research Program

E80: The Impact of Postmastectomy Radiation Therapy on Direct-to-Implant Reconstruction

E81: Can Completion Axillary Lymph Node Dissection be Omitted after Neoadjuvant Endocrine Therapy?

E83: Locoregional Therapy for Inflammatory Breast Cancer: How Much is Enough?

E84: Changes in Breast Cancer Staging during the COVID-19 Pandemic: A National Cancer Database Analysis

E85: Advancing Treatment for Triple Negative Breast Cancer: Liposomal Oncolytic Adenovirus as a Novel Neoadjuvant Therapy

E86: Residual axillary nodal disease in clinical N1 breast cancer patients undergoing neoadjuvant chemotherapy: Can sentinel lymph node biopsy alone suffice?

E87: Breast Cancer and Hormone Therapy in Transgender Patients: A Review of Case and Cohort Studies

E88: CHEK2 Mutation and Breast Cancer: A retrospective review of management and surveillance compliance

E89: Patient Reported Outcomes for Modified Oncoplastic Lift and Lymphatic Excision and Reconstruction using BREAST Q

E9: Impact of Close Margins in Breast Conserving Surgery Following Neoadjuvant Chemotherapy

E90: Triple-Negative Breast Cancer in Young Black Women

E91: Insurance Status Influences Access to Care Among Hispanic Women with Breast Cancer

E92: Early Compliance with Commission on Cancer Operative Standards for Breast Cancer Surgery

E93: Frailty and Malnutrition in Surgical Outcomes of Elderly Breast Cancer Patients

E94: Neoadjuvant Hormonal Therapy in Invasive Ductal vs Lobular Carcinoma of the Breast: A Comparative Analysis

E95: Genomic Data Contribution from Breast Cancer Survivors in the All Of Us Research Program

P1: High spermidine expression is associated with high cell proliferation and worse survival but respond better to immunotherapy in ER-positive/HER2-negative breast cancer.

P2: Impact of Race and Ethnicity on Recurrence Risk in Patients with Ductal Carcinoma in Situ Treated with Breast-Conserving Surgery

P3: Patient Satisfaction Following Pilot of Decision Aid to Reduce Overtreatment of Older Women with Early-Stage Breast Cancer

P4: Breast conserving therapy is a safe option for women under 40 diagnosed with breast cancer

P5: In-Breast Tumor Progression During Neoadjuvant Chemotherapy- Impact on and Factors Influencing Distant Recurrence-Free Survival

P6: Comparison of Survival Outcomes for Select Patients with Stage III vs Stage IV Disease

P7: The clinical relevance of Mu-opioid receptor gene (OPRM1) expression in breast cancer

P8: Reducing Tumor Recurrence and Adhesion Development with Deionized Water in Mouse Models